Insmed's stock surges 27% after positive Phase 2b trial results for its pulmonary hypertension treatment, positioning it as a potential breakthrough therapy.
Uber and Wayve partner to launch driverless robotaxi trials in London, marking a pivotal moment for UK autonomy.
Insmed's stock surges 27% after positive Phase 2b trial results for its pulmonary hypertension treatment, positioning it as a potential breakthrough therapy.
Uber and Wayve partner to launch driverless robotaxi trials in London, marking a pivotal moment for UK autonomy.